stocks logo

SCPH

scPharmaceuticals Inc
$
5.380
+0.25(4.873%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
5.390
Open
5.140
VWAP
5.28
Vol
307.03K
Mkt Cap
284.02M
Low
5.060
Amount
1.62M
EV/EBITDA(TTM)
--
Total Shares
36.05M
EV
254.30M
EV/OCF(TTM)
--
P/S(TTM)
5.67
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company’s strategy is to develop therapies for subcutaneous administration that have previously been limited to intravenous (IV) delivery. Its commercial product, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Company’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
26.63M
+119.19%
-0.128
-59.22%
20.61M
+105.53%
-0.246
-33.75%
15.41M
+91.38%
-0.298
-32.27%
Estimates Revision
The market is revising No Change the revenue expectations for scPharmaceuticals Inc. (SCPH) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 106.92%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+106.92%
In Past 3 Month
5 Analyst Rating
up Image
189.96% Upside
Wall Street analysts forecast SCPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SCPH is 15.60 USD with a low forecast of 11.00 USD and a high forecast of 25.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
up Image
189.96% Upside
Current: 5.380
sliders
Low
11.00
Averages
15.60
High
25.00
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$18
2025-03-20
Reason
Maxim Group
Naz Rahman
Strong Buy
Maintains
$20 → $12
2025-03-20
Reason
Maxim analyst Naz Rahman lowered the firm's price target on scPharmaceuticals to $12 from $20 but keeps a Buy rating on the shares after its Q4 results. The firm expects the benefits from both the Medicare redesign and CKD to materialize in Q3 and be more pronounced in Q4, though it also sees sales in Q1 to be lower than Q4 sales due to healthcare plans and deductibles resetting, the analyst tells investors in a research note. Maxim adds that the management's various initiatives to accelerate Furoscix sales trajectory are now coming to fruition, also stating that the market opportunity for chronic heart failure and CKD patients remains significant and Furoscix continues to see positive reception and adoption.
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$18
2025-03-07
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$18
2025-03-03
Reason
Craig-Hallum
Chase Knickerbocker
Strong Buy
Maintains
$16 → $12
2024-11-14
Reason
Craig-Hallum lowered the firm's price target on scPharmaceuticals to $12 from $16 and keeps a Buy rating on the shares. The firm notes the company's Q3 report is likely to leave investors unsatisfied. Craig-Hallum believes that it is important for investors to understand that scPharmaceuticals is now seeing more demand from IDNs/hospital systems, and this volume and revenue is not reflected in the script data provided.
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$18
2024-11-14
Reason

Valuation Metrics

The current forward P/E ratio for scPharmaceuticals Inc (SCPH.O) is -6.56, compared to its 5-year average forward P/E of -4.31. For a more detailed relative valuation and DCF analysis to assess scPharmaceuticals Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.31
Current PE
-6.56
Overvalued PE
-3.10
Undervalued PE
-5.52

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.92
Current EV/EBITDA
-7.36
Overvalued EV/EBITDA
-1.21
Undervalued EV/EBITDA
-4.63

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
18.90
Current PS
2.95
Overvalued PS
48.06
Undervalued PS
-10.27

Financials

Annual
Quarterly
FY2025Q1
YoY :
+92.59%
11.75M
Total Revenue
FY2025Q1
YoY :
+11.99%
-17.76M
Operating Profit
FY2025Q1
YoY :
+39.93%
-19.74M
Net Income after Tax
FY2025Q1
YoY :
+2.78%
-0.37
EPS - Diluted
FY2025Q1
YoY :
-100.00%
N/A
Free Cash Flow
FY2025Q1
YoY :
-0.41%
70.46
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q1
YoY :
-27.34%
-167.99
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
2.0M
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1900% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
208.1K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
500.0K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

SCPH News & Events

Events Timeline

2025-05-14 (ET)
2025-05-14
16:21:25
scPharmaceuticals reports Q1 EPS (37c), consensus (28c)
select
2025-03-19 (ET)
2025-03-19
16:06:55
scPharmaceuticals reports Q 4EPS (35c), consensus (39c)
select
2025-03-06 (ET)
2025-03-06
16:03:55
scPharmaceuticals announces FDA approval of Furoscix indication expansion
select
Sign Up For More Events

News

9.5
05-15NASDAQ.COM
ScPharmaceuticals Doubles FUROSCIX Sales In Q1, Launches In CKD, Eyes Autoinjector Filing In Q3
1.0
05-01Yahoo Finance
scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences
8.0
03-19TipRanks
Options Volatility and Implied Earnings Moves Today, March 19, 2025
Sign Up For More News

FAQ

arrow icon

What is scPharmaceuticals Inc (SCPH) stock price today?

The current price of SCPH is 5.38 USD — it has increased 4.87 % in the last trading day.

arrow icon

What is scPharmaceuticals Inc (SCPH)'s business?

arrow icon

What is the price predicton of SCPH Stock?

arrow icon

What is scPharmaceuticals Inc (SCPH)'s revenue for the last quarter?

arrow icon

What is scPharmaceuticals Inc (SCPH)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for scPharmaceuticals Inc (SCPH)'s fundamentals?

arrow icon

How many employees does scPharmaceuticals Inc (SCPH). have?

arrow icon

What is scPharmaceuticals Inc (SCPH) market cap?